Forkhead box M1 (FOXM1) is a transcription factor in the forkhead (FOX) family, which is required for cellular proliferation in normal and neoplastic cells. FOXM1 is highly expressed in many different cancers, and its expression is associated with a higher tumor stage and worse patient-related outcomes. Abnormally high expression of FOXM1 in cancers compared to normal tissue makes FOXM1 an attractive target for pharmacological inhibition. FOXM1-inhibiting agents and specific FOXM1-targeted small-molecule inhibitors have been developed in the lab and some of them have shown promising efficacy and safety profiles in mouse models. While the future goal is to translate FOXM1 inhibitors to clinical trials, potential synergistic drug combinations can maximize anti-tumor efficacy while minimizing off-target side effects. Hence, we discuss the rationale and efficacy of all previously studied drug combinations with FOXM1 inhibitors for cancer therapies.
叉头框M1（FOXM1）是叉头框（FOX）家族中的一种转录因子，对正常细胞和肿瘤细胞的增殖至关重要。FOXM1在多种癌症中高度表达，其表达水平与更高的肿瘤分期及更差的患者预后相关。相较于正常组织，FOXM1在癌症中的异常高表达使其成为药物抑制的潜在靶点。目前实验室已开发出FOXM1抑制剂及特异性靶向FOXM1的小分子抑制剂，其中部分在动物模型中显示出良好的疗效和安全性。尽管未来目标是将FOXM1抑制剂推向临床试验，但潜在的协同药物组合有望在最大化抗肿瘤疗效的同时减少脱靶副作用。因此，本文系统综述了所有已研究的FOXM1抑制剂联合用药方案在癌症治疗中的理论基础与疗效。
The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment
肿瘤(癌症)患者之家